Methods and compositions for preventing, reducing, or eliminating toxicity caused by acetaminophen (APAP)

Abstract

The present invention provides methods and compositions for preventing, reducing, or eliminating the toxicity caused by acetaminophen (APAP). [Solution] A method for preventing, reducing, reducing or eradicating toxicity caused by acetaminophen (APAP) or its derivatives, comprising administering a first compound selected from the group consisting of Eudragit S100, Pluronic F68, Naringenin, Kaempferol and any combination thereof, to a subject in need of it in an amount effective to prevent, reduce or eradicate toxicity caused by APAP. The toxicity caused by APAP is nephrotoxicity and / or hepatotoxicity.

Claims

1. A pharmaceutical composition for preventing, reducing, or eliminating nephrotoxicity caused by acetaminophen (APAP), An effective amount of sucralose, or a combination of sucralose and one or more compounds selected from the group consisting of Eudragit® S100, Pluronic® F68, and Kaempferol; or A pharmaceutical composition comprising an effective amount of a compound selected from the group consisting of Eudragit® S100, Pluronic® F68, Kaempferol, Sucralose, and any combination thereof.

2. A pharmaceutical composition for preventing, reducing, or eliminating nephrotoxicity caused by acetaminophen (APAP), A pharmaceutical composition comprising an effective amount of a first compound selected from the group consisting of Eudragit® S100, Pluronic® F68, Kaempferol, and any combination thereof.

3. The pharmaceutical composition according to claim 1 or 2, wherein the composition is used as an antidote, an acetaminophen nephrotoxicity inhibitor, or an inhibitor.

4. The pharmaceutical composition according to claim 2, wherein the first compound comprises a combination of Eudragit® S100 and Pluronic® F68.

5. The pharmaceutical composition according to claim 2, further comprising a second compound selected from the group consisting of naringenin, sucralose, luteolin, and any combination thereof.

6. The first and second compounds administered to the subjects are as follows: (i) A combination of Eudragit® S100 and sucralose; (ii) A combination of Pluronic® F68 and sucralose; (v) combination of Eudragit® S100, sucralose and luteolin; and (viii) A combination of Eudragit® S100, Pluronic® F68, and Naringenin; The pharmaceutical composition according to claim 5, which is a combination selected from the group consisting of the following.

7. The compound is naringenin, luteolin, menthol, polyethylene glycol sorbitan monolaurate, microcrystalline cellulose, Brij® 35, saccharin, Cremofor® RH40, crospovidone, sodium starch glycolate, croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, Dextrate NF hydrate, citric acid, Cremofor® EL, Aerosil® 200, Myrj® 52, sorbic acid, lemon oil, hydroxypropyl cellulose, sorbitol, acesulfame potassium, hydroxypropyl methylcellulose, lactose monohydrate, maltodextrin, Brij® 58, Brij® 76, Tween® 80, Tween® 40, polyethylene glycol (PEG) 400, PEG 4000, PEG The pharmaceutical composition according to claim 1 or 2, which is combined with an additional compound selected from the group consisting of 8000, Span® 60, sodium benzoate, hydroxyethyl methylcellulose, methylcellulose, Span® 80, sodium cyclamate, glyceryl behenate, oxide red, glycerin monostearate, copovidone K28, starch acetate, magnesium stearate, sodium lauryl sulfate, providedon K30, PEG 2000, and any combination thereof.

8. The pharmaceutical composition according to claim 1 or 2, wherein nephrotoxicity is defined as damage to the kidneys.

9. The pharmaceutical composition according to claim 1 or 2, wherein the nephrotoxicity is acute kidney injury.

10. The use of a compound for the manufacture of a drug for preventing, reducing, or eliminating nephrotoxicity caused by acetaminophen (APAP), wherein the compound is (ii) sucralose, or a combination of sucralose and one or more compounds selected from the group consisting of Eudragit® S100, Pluronic® F68, and kaempferol; or (iii) Use of a substance selected from the group consisting of Eudragit® S100, Pluronic® F68, Kaempferol, sucralose and / or any combination thereof.

11. The use of a first compound for the manufacture of a drug for preventing, reducing, or eradicating nephrotoxicity caused by acetaminophen (APAP), The first compound is selected from the group consisting of Eudragit® S100, Pluronic® F68, Kaempferol, and any combination thereof.

12. The use according to claim 10 or 11, wherein the compound is used as an antidote, an anti-acetaminophen toxicity agent, or an inhibitor.

13. The use according to claim 11, wherein the first compound comprises a combination of Eudragit® S100 and Pluronic® F68.

14. The use according to claim 11, wherein the first compound is administered together with a second compound selected from the group consisting of naringenin, mannitol, sucralose, luteolin, and any combination thereof.

15. The first compound and the second compound are as follows: (i) A combination of Eudragit® S100 and sucralose; (ii) A combination of Pluronic® F68 and sucralose; (v) combination of Eudragit® S100, sucralose and luteolin; and (viii) A combination of Eudragit® S100, Pluronic® F68, and Naringenin; The use according to claim 14, which is a combination selected from the group consisting of the following.

16. The compound is naringenin, luteolin, menthol, polyethylene glycol sorbitan monolaurate, microcrystalline cellulose, Brij® 35, saccharin, Cremofor® RH40, crospovidone, sodium starch glycolate, croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, Dextrate NF hydrate, citric acid, Cremofor® EL, Aerosil® 200, Myrj® 52, sorbic acid, lemon oil, hydroxypropyl cellulose, sorbitol, acesulfame potassium, hydroxypropyl methylcellulose, lactose monohydrate, maltodextrin, Brij® 58, Brij® 76, Tween® 80, Tween® 40, PEG 400, polyethylene glycol (PEG) 4000, PEG The use according to claim 10 or 11, in combination with additional compounds selected from the group consisting of 8000, Span® 60, sodium benzoate, hydroxyethyl methylcellulose, methylcellulose, Span® 80, sodium cyclamate, glyceryl behenate, oxide red, glycerin monostearate, copovidone K28, starch acetate, magnesium stearate, sodium lauryl sulfate, providedon K30, PEG 2000, and any combination thereof.

17. The use according to claim 10 or 11, wherein nephrotoxicity is kidney damage.

18. The use according to claim 10 or 11, wherein the nephrotoxicity is acute kidney injury.

Images